Skip to content
The Nexus
DossierENTITY

Tregzi

Coverage of Tregzi in the Nexus archive.

Earliest in view: Jul 1 · 11:38 UTCMost recent: Jul 1 · 18:00 UTC
Co-mentioned in this coverage
FDAorganization2graft-versus-host diseasetopic2Orca-Ttopic1stem cell transplantstopic1hematologic cancerstopic1Orca Bioorganization1Nate Fernhoffperson1blood cancertopic1stem cell transplanttopic1
Recent coverage
  • HEALTHJul 1 · 18:00 UTCMEDPAGE TODAY
    Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

    The FDA approved Orca-T (Tregzi), an allogeneic regulatory T cell-based immunotherapy product combined with hematopoietic stem and progenitor cells and T cells, to prevent graft-versus-host disease (GVHD) in stem cell transplants for hematologic cancers.

  • HEALTHJul 1 · 11:38 UTCSTAT NEWS
    STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

    The FDA approved Orca Bio's T cell therapy, Tregzi, which reduces immune reaction risks for blood cancer patients undergoing stem cell transplants. The therapy offers a curative alternative to traditional transplants that carry high risks of chronic graft-versus-host disease.